Fragile X Syndrome - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 117
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FC04677E930EN
Leaflet:

Download PDF Leaflet

Fragile X Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fragile X Syndrome - Pipeline Review, H2 2016’, provides an overview of the Fragile X Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome
  • The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Fragile X Syndrome Overview
Therapeutics Development
Pipeline Products for Fragile X Syndrome - Overview
Pipeline Products for Fragile X Syndrome - Comparative Analysis
Fragile X Syndrome - Therapeutics under Development by Companies
Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes
Fragile X Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fragile X Syndrome - Products under Development by Companies
Fragile X Syndrome - Products under Investigation by Universities/Institutes
Fragile X Syndrome - Companies Involved in Therapeutics Development
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Anavex Life Sciences Corp.
Confluence Pharmaceuticals LLC
DRI Biosciences Corporation
Eli Lilly and Company
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
Kareus Therapeutics, SA
Marinus Pharmaceuticals, Inc.
Neuren Pharmaceuticals Limited
Neuron Biopharma SA
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acamprosate calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMO-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cercosporamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flindokalner - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gaboxadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-655 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KU-046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metadoxine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNZ-2591 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGE-872 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-278 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TC-2153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trofinetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fragile X Syndrome - Dormant Projects
Fragile X Syndrome - Discontinued Products
Fragile X Syndrome - Product Development Milestones
Featured News & Press Releases
Jul 19, 2016: Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
Jun 28, 2016: Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
Jun 27, 2016: Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures
Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
Jun 07, 2016: AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome
Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
Dec 07, 2015: Neuren’s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome
Nov 30, 2015: Neuren receives grant of composition patent in Europe for NNZ-2591
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 117

LIST OF TABLES

Number of Products under Development for Fragile X Syndrome, H2 2016
Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Fragile X Syndrome - Pipeline by Aelis Farma SAS, H2 2016
Fragile X Syndrome - Pipeline by Alcobra Ltd, H2 2016
Fragile X Syndrome - Pipeline by AMO Pharma Limited, H2 2016
Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp., H2 2016
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
Fragile X Syndrome - Pipeline by DRI Biosciences Corporation, H2 2016
Fragile X Syndrome - Pipeline by Eli Lilly and Company, H2 2016
Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016
Fragile X Syndrome - Pipeline by Kareus Therapeutics, SA, H2 2016
Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H2 2016
Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc., H2 2016
Fragile X Syndrome - Pipeline by Sage Therapeutics, Inc., H2 2016
Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Fragile X Syndrome - Dormant Projects, H2 2016
Fragile X Syndrome - Dormant Projects (Contd..1), H2 2016
Fragile X Syndrome - Discontinued Products, H2 2016 103

LIST OF FIGURES

Number of Products under Development for Fragile X Syndrome, H2 2016
Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Acute Coronary Syndrome - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 109 pages

Ask Your Question

Fragile X Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: